Physician profile
Taavi Vint
NPI 1649839598
$3,390.08
in general payments reported to CMS, 2019-2025
19 companies · $632 in 2025
The $632 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $989 · 2022: $507 · 2023: $239 · 2024: $1,023 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $624.86 | 2021-2025 | |
| Abbvie INC. | $608.73 | 2021-2025 | |
| Lundbeck LLC | $338.76 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.89 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $263.59 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $184.76 | 2022-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $124.71 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $120.86 | 2024 | Nucala |
| Sobi, INC | $120.75 | 2023 | |
| Stemline Therapeutics INC. | $115.61 | 2022 | |
| Avanir Pharmaceuticals, INC. | $110.07 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.97 | 2023 | |
| Supernus Pharmaceuticals, INC. | $94.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $84.45 | 2024 | Quviviq |
| Gilead Sciences, INC. | $79.13 | 2024 | Veklury |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $36.11 | 2024 | Fanapt |
| Corium, LLC | $24.81 | 2024 | Azstarys |
| Almatica Pharma LLC | $20.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taavi Vint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.